Concenter BioPharma
Tel Aviv, Israel· Est.
Israeli biotech advancing a first‑in‑class insulin‑resistance therapy for type‑2 diabetes.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli biotech advancing a first‑in‑class insulin‑resistance therapy for type‑2 diabetes.
MetabolismEndocrinology
Technology Platform
A protected platform of non‑steroidal chemical complexes that act as anti‑inflammatory, iron‑chelating, and antibiotic agents, providing synergistic mechanisms to treat insulin resistance and related metabolic disorders.
Opportunities
Large unmet need for insulin‑resistance‑targeted therapies in a $850 billion diabetes market; ability to leverage expedited regulatory pathways and platform scalability.
Risk Factors
Early‑stage clinical data, limited financial resources, and intense competition from established diabetes drug classes.
Competitive Landscape
Competes with GLP‑1, SGLT2, and metformin classes, but differentiates through a novel multi‑mechanistic approach directly addressing insulin resistance.